- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.07. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial | 260 | GlobeNewswire (Europe) | 90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated... ► Artikel lesen | |
| 25.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer | 241 | GlobeNewswire (Europe) | Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage... ► Artikel lesen | |
| 18.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University | 273 | GlobeNewswire (Europe) | Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE... ► Artikel lesen | |
| 10.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial | 326 | GlobeNewswire (Europe) | Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected... ► Artikel lesen | |
| 04.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial | 241 | GlobeNewswire (Europe) | MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE... ► Artikel lesen | |
| 03.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion | 280 | GlobeNewswire (Europe) | Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 02.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Director | 3 | GlobeNewswire (USA) | ||
| 22.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.05. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.04. | MAIA Biotechnology opens first U.S. site for lung cancer trial | 1 | Investing.com | ||
| 16.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | 287 | GlobeNewswire (Europe) | Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC... ► Artikel lesen | |
| 16.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy | 1 | Seeking Alpha | ||
| 08.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy | 228 | GlobeNewswire (Europe) | Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability... ► Artikel lesen | |
| 08.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.04. | MAIA Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 431 | GlobeNewswire (Europe) | Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a... ► Artikel lesen | |
| 27.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.03. | MAIA Biotechnology, Inc. - 10-K, Annual Report | 2 | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 114,42 | +0,60 % | Big Pharma sucht den nächsten Blockbuster - weshalb Zelltherapien wieder stärker in den Fokus rücken | ||
| ABBVIE | 227,60 | -0,22 % | Genmab A/S and AbbVie: Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE DLBCL-1 trial and was not met Genmab A/S(Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today... ► Artikel lesen | |
| ABBOTT LABORATORIES | 90,88 | +0,20 % | Benchmark reiterates Buy on Abbott Labs stock, cites guidance raise | ||
| INNOCAN PHARMA | 1,800 | +4,35 % | InnoCan Pharma verliert 1,6%: Jetzt zählt nur noch diese eine Marke - So starte ich in die Handelswoche | ||
| SCHOTT PHARMA | 20,200 | -0,74 % | Aktie der Woche: Schott Pharma Video | Schott Pharma ist unsere Aktie der Woche. Die Aktie hat in den vergangenen Wochen deutlich zugelegt - getrieben von einer angehobenen Prognose und positiven Reaktionen der Analysten. Doch wie belastbar... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 73,00 | +0,41 % | Edwards Lifesciences Q2 Profit Down; Raises 2026 Sales Outlook | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) on Thursday reported a lower profit in the second quarter, as revenues increased 14%.Net income declined to $241.9 million or $0.42 per... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 23,000 | +2,45 % | ASSEMBLY BIOSCIENCES INC in stabiler Marktphase | ||
| PENTIXAPHARM | 2,010 | -1,47 % | Pentixapharm: Discount-Einstieg mit Phase-III-Fantasie | Bei Pentixapharm verschiebt sich der Fokus derzeit von der klinischen Fantasie auf die Finanzierung der nächsten Entwicklungsschritte. Das muss kein Widerspruch sein. Denn gerade bei Biotech-Unternehmen... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,797 | +1,53 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 211,80 | 0,00 % | Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug | ||
| MEDPACE | 530,00 | +0,23 % | Morning Market Movers: 707 Cayman, Zhongchao, NVE Corporation, Medpace See Big Swings | BEIJING (dpa-AFX) - At 8:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| UNITED THERAPEUTICS | 469,00 | +0,90 % | Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now? | ||
| ZEALAND PHARMA | 39,130 | +0,23 % | Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | ||
| UCB | 246,10 | +0,37 % | UCB: Gute Aktie - billigerer Einstieg | Eine der erfolgreichsten europäischen Pharmaaktien ist die von UCB (WKN: 852738) aus Belgien. Innerhalb der vergangenen drei Jahre hat sich der Kurs mehr als verdreifacht. Auslöser war das Blockbuster-Medikament... ► Artikel lesen | |
| JAGUAR HEALTH | 1,000 | +3,81 % | Jaguar Health, Inc.: Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure Due to Microvillus Inclusion Disease | Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID SAN FRANCISCO, CA /... ► Artikel lesen |
Das Unternehmen MAIA BIOTECHNOLOGY INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,005 (+0,40 %) liegt der Kurs bei 1,245 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.